CompletedPhase 3NCT00516503
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
Studying Tumor of hematopoietic and lymphoid tissues
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Debra Barton, RN, PhD, AOCN, FAANMayo Clinic
- Intervention
- baclofen/amitriptyline/ketamine gel(drug)
- Enrollment
- 208 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2010
Study locations (30)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- St. Joseph Medical Center, Bloomington, Illinois, United States
- Graham Hospital, Canton, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- Eureka Community Hospital, Eureka, Illinois, United States
- Galesburg Clinic, PC, Galesburg, Illinois, United States
- Galesburg Cottage Hospital, Galesburg, Illinois, United States
- Mason District Hospital, Havana, Illinois, United States
- Hopedale Medical Complex, Hopedale, Illinois, United States
- Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
- McDonough District Hospital, Macomb, Illinois, United States
- Moline, Illinois, United States
- Community Cancer Center, Normal, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00516503 on ClinicalTrials.govOther trials for Tumor of hematopoietic and lymphoid tissues
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07249346Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationHannah Choe, MD
- RECRUITINGPHASE1NCT06904066Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07270770BY002 IIT Study in R/R Acute LeukemiaThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07257419CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company
- RECRUITINGPHASE1, PHASE2NCT07471789Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).Gyala Therapeutics
- RECRUITINGNANCT07051525Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and FeverPeter MacCallum Cancer Centre, Australia
- RECRUITINGPHASE1NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsITM Solucin GmbH
See all trials for Tumor of hematopoietic and lymphoid tissues →